Overview
Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and metabolic diseases. Its stated purpose is to deliver life-changing therapies to people living with rare disease. The company’s key marketed medicine is FILSPARI (sparsentan), approved in the United States for certain patients with IgA nephropathy and focal segmental glomerulosclerosis; its pipeline includes investigational pegtibatinase for classical homocystinuria.[1][2][3]
Headquartered in San Diego, Travere also lists offices in Dublin and Rapperswil, indicating a presence in the United States and Europe. Its company profile describes a workforce of about 500 people. Revenue was $490.7 million in fiscal 2025; in the first half of 2026, the company reported $296.8 million in revenue.[4][5][6][7][8] [1][2][3][4][5][6][7][8][3][5][6]
Products & services
Travere’s marketed products include FILSPARI® (sparsentan), an oral, once-daily dual endothelin and angiotensin receptor antagonist. It is approved in the United States to slow kidney-function decline in adults with primary IgA nephropathy at risk of progression, and to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis who do not have nephrotic syndrome.[9][10][11][3] The company also markets THIOLA® and THIOLA EC® (tiopronin), approved in the United States to help prevent cystine kidney-stone formation in patients with severe homozygous cystinuria. THIOLA EC is an enteric-coated tablet available in 100 mg and 300 mg strengths.[12][13][14]
Pegtibatinase is an investigational enzyme-replacement therapy candidate for classical homocystinuria, intended to reduce total homocysteine; it is not approved. Its pivotal Phase 3 HARMONY trial resumed enrollment in the first quarter of 2026 following a pause related to manufacturing scale-up.[15][16][17] In the second quarter of 2026, FILSPARI generated $141.1 million in U.S. net product sales, approximately 87.5% of Travere’s $161.352 million in total net product sales for the quarter; for the first half of 2026, it generated $246.2 million, approximately 86.1% of total net product sales of $285.844 million. These percentages are calculated from the reported figures.[18][8] [9][10][11][3][12][13][14][15][16][17][18][8][8][3][14][17]
Geographic presence
Travere Therapeutics’ commercial footprint is centered on the United States. For FILSPARI, CSL Vifor holds commercialization rights in Europe, Australia and New Zealand, and rights in additional countries including Brazil, Chile, Israel and several Gulf states; the company reported launches in Germany, Austria, Switzerland, Luxembourg and the UK by January 2026. Canada and Mexico were described as subject to a right to negotiate, rather than as existing licensed territories.[9][19][20][21][22]
For 2025, Travere reported $410.5 million in U.S. net product sales and $490.7 million in total revenue, including license and collaboration revenue. Its filings do not provide a country- or region-level breakdown of total revenue. The company reports one operating segment, and long-lived assets outside the U.S. were immaterial in its 2026 second-quarter filing.[7][23][24][25]
The company identifies San Diego, California as its headquarters and lists additional offices in Dublin, Ireland, and Rapperswil, Switzerland. Its public materials do not give employee distribution by location.[4][26][27] [9][19][20][7][24][25][4][26][21][22][23][27]
Business segments
Travere Therapeutics reports one business segment, focused on identifying, developing and delivering therapies for rare kidney and metabolic diseases. The company does not disclose separate segment-level contribution percentages; its reported activities are grouped within this single segment.[28][24] [28][24]
Company history
Travere Therapeutics began as Retrophin, LLC in March 2011, incorporated as Retrophin, Inc. in September 2012, and became publicly traded after a reverse merger with Desert Gateway, Inc. on December 18, 2012.[29][30] In 2014, Retrophin acquired Manchester Pharmaceuticals, adding marketed products including Chenodal, and licensed U.S. rights to Thiola; later that year, the board replaced Martin Shkreli as CEO.[31][32][33]
In 2015, the FDA approved Cholbam, Retrophin’s first newly approved drug, for certain bile-acid synthesis and peroxisomal disorders. Eric Dube became president and CEO in January 2019; later that year, the FDA approved Thiola EC. In November 2020, the company adopted the name Travere Therapeutics, and acquired Orphan Technologies, adding the investigational HCU therapy OT-58.[29][34][35][36]
In February 2023, FILSPARI (sparsentan) received accelerated FDA approval for adults with primary IgA nephropathy; in October, Travere sold its bile-acid product portfolio, including Cholbam, to Mirum. The European Commission granted FILSPARI conditional marketing authorization for IgA nephropathy in April 2024, and the FDA converted its U.S. approval to full approval in September 2024. In April 2026, the FDA approved FILSPARI for focal segmental glomerulosclerosis (FSGS) in adults and children aged eight and older.[37][38][39][40][3] [29][30][31][32][33][34][35][36][37][38][39][40][3]
Sources
- Travere Therapeutics, Inc. — Full financial report (2025 Y)
- Travere Therapeutics, Inc. — Full financial report (2026 Q 2)
- ir.travere.com[3]
- travere.com[5]
- travere.com[6]
- travere.com[14]
- travere.com[17]
- Travere Therapeutics, Inc. — Press release (2026 Q 2)[18]
- travere.com[21]
- ir.travere.com[22]
- ir.travere.com[23]
- travere.com[27]
- www.sec.gov[29]
- ir.travere.com[30]
- ir.travere.com[31]
- ir.travere.com[32]
- ir.travere.com[33]
- ir.travere.com[34]
- ir.travere.com[35]
- ir.travere.com[36]
- ir.travere.com[37]
- ir.travere.com[38]
- ir.travere.com[39]
- ir.travere.com[40]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore Travere Therapeutics, Inc. in Finbar ↗